Ultomiris (ravulizumab) — Alexion Pharmaceuticals’ approved therapy for certain complement-associated disorders — prevents relapses in adults with neuromyelitis optica…
Articles by Marta Figueiredo, PhD
Uplizna (inebilizumab-cdon) works to treat people with neuromyelitis optica spectrum disorder (NMOSD) regardless of whether such patients carry…
Giving immunosuppressive therapy to patients with antibodies against aquaporin-4 protein (AQP4) and optic neuritis but no symptoms may help resolve…
An analysis of pharmacological data supports the observed clinical efficacy of Soliris (eculizumab) in significantly reducing relapses in…
SB12, Samsung Bioepis’ biosimilar candidate of Soliris (eculizumab), is comparable to the original medication in terms of safety,…
Long-term treatment with Uplizna (inebilizumab-cdon) safely and effectively reduced the frequency of attacks in the 12 neuromyelitis optica…
Treatment with Horizon Therapeutics’ Uplizna (inebilizumab) leads to a rapid and sustained drop in immune B-cells in adults with…
Note: This story was updated Nov. 2, 2021, to note that Soliris is taken every two weeks, rather than…
Long-term treatment with Enspryng (satralizumab) safely and sustainably prevents relapses in adolescents and adults with neuromyelitis optica spectrum…
The SPHERES registry, an observational study to better understand the underlying mechanisms and clinical course of neuromyelitis optica…